Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Frequently asked questions
What sector does Phio Pharmaceuticals Corp (PHIO) operate in?
Phio Pharmaceuticals Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Phio Pharmaceuticals Corp (PHIO) current stock price?
As of the latest data, Phio Pharmaceuticals Corp stock price is $0.86, with a previous close of $0.85. Phio Pharmaceuticals Corp gained $0.00 in the last trading session, representing a 0.56% increase.
What is Phio Pharmaceuticals Corp (PHIO) current market capitalization?
Phio Pharmaceuticals Corp market cap is approximately 9.93 million.
What is Phio Pharmaceuticals Corp (PHIO) Earnings Per Share (EPS)?
The trailing EPS is -$1.27, and the forward EPS is -$0.61.
What is Phio Pharmaceuticals Corp (PHIO) EBITDA?
Phio Pharmaceuticals Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -4.27 million.
Does Phio Pharmaceuticals Corp (PHIO) pay dividends?
No. Phio Pharmaceuticals Corp does not pay a dividend.
What is Phio Pharmaceuticals Corp (PHIO) beta (volatility) score?
Phio Pharmaceuticals Corp has a beta of 0.802, meaning its volatility is roughly in line with the market.
